Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease

Von Ungern-Sternberg, Saskia N. I.; Zernecke, Alma; Seizer, Peter

doi:10.3390/ijms19020507

Open AccessReview

Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease

by

Saskia N. I. Von Ungern-Sternberg

¹,

Alma Zernecke

^2,*,† and

Peter Seizer

^1,*,†

¹

Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Eberhard Karls-Universität Tübingen, 72076 Tübingen, Germany

²

Institut für Experimentelle Biomedizin, Universitätsklinikum Würzburg, 97080 Würzburg, Germany

^*

Authors to whom correspondence should be addressed.

^†

These authors contribute equally to this work.

Int. J. Mol. Sci. 2018, 19(2), 507; https://doi.org/10.3390/ijms19020507

Submission received: 20 December 2017 / Revised: 31 January 2018 / Accepted: 1 February 2018 / Published: 8 February 2018

(This article belongs to the Special Issue Roles of Cardiovascular Active Substances and Cellular Events in the Homeostasis of Cardiovascular Systems)

Download

Browse Figures

Versions Notes

Abstract

The receptor EMMPRIN is involved in the development and progression of cardiovascular diseases and in the pathogenesis of myocardial infarction. There are several binding partners of EMMPRIN mediating the effects of EMMPRIN in cardiovascular diseases. EMMPRIN interaction with most binding partners leads to disease progression by mediating cytokine or chemokine release, the activation of platelets and monocytes, as well as the formation of monocyte-platelet aggregates (MPAs). EMMPRIN is also involved in atherosclerosis by mediating the infiltration of pro-inflammatory cells. There is also evidence that EMMPRIN controls energy metabolism of cells and that EMMPRIN binding partners modulate intracellular glycosylation and trafficking of EMMPRIN towards the cell membrane. In this review, we systematically discuss these multifaceted roles of EMMPRIN and its interaction partners, such as Cyclophilins, in cardiovascular disease.

Keywords: cardiovascular disease; immunoglobulin superfamily; inflammation; platelets; monocyte-platelet aggregates

Share and Cite

MDPI and ACS Style

Von Ungern-Sternberg, S.N.I.; Zernecke, A.; Seizer, P. Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease. Int. J. Mol. Sci. 2018, 19, 507. https://doi.org/10.3390/ijms19020507

AMA Style

Von Ungern-Sternberg SNI, Zernecke A, Seizer P. Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease. International Journal of Molecular Sciences. 2018; 19(2):507. https://doi.org/10.3390/ijms19020507

Chicago/Turabian Style

Von Ungern-Sternberg, Saskia N. I., Alma Zernecke, and Peter Seizer. 2018. "Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease" International Journal of Molecular Sciences 19, no. 2: 507. https://doi.org/10.3390/ijms19020507

APA Style

Von Ungern-Sternberg, S. N. I., Zernecke, A., & Seizer, P. (2018). Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease. International Journal of Molecular Sciences, 19(2), 507. https://doi.org/10.3390/ijms19020507

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI